Actionnariat et activité des initiés pour Ultragenyx Pharmaceutical Inc. (RARE): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $12.88 |
| Capitalisation | $1.3B |
| Bourse | NASDAQ |
| Pays | US |
Transactions d'Initiés Récentes
| Date | Initié | Type | Actions | Valeur |
|---|---|---|---|---|
| 2026-09-15 | Huizenga Theodore Alan | S-Sale | 1,283 | $17K |
| 2026-09-03 | Huizenga Theodore Alan | S-Sale | 161 | $2K |
| 2026-08-03 | Parschauer Karah Herdman | S-Sale | 1,900 | $47K |
| 2026-08-03 | Horn Howard | S-Sale | 4,696 | $117K |
| 2026-07-01 | Horn Howard | S-Sale | 4,698 | $156K |
| 2026-06-15 | Sanders Corazon (Corsee) D. | S-Sale | 2,000 | $50K |
| 2026-06-15 | Parschauer Karah Herdman | S-Sale | 1,899 | $47K |
| 2026-06-01 | Horn Howard | S-Sale | 4,653 | $111K |
| 2026-05-14 | Fust Matthew K | A-Award | 7,751 | |
| 2026-05-14 | Fust Matthew K | A-Award | 14,058 | $363K |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $161.1M | $100.5M | $113.4M | $433.6M | $713.5M | $307.6M | $132.9M | $213.6M | $173.7M | $434.0M |
| Placements à Court Terme | $219.0M | $134.0M | $346.3M | $321.6M | $488.0M | $432.6M | $614.8M | $363.6M | $436.3M | $259.0M |
| Créances | 0 | $5.2M | $12.7M | $32.8M | $23.1M | $44.4M | $40.4M | $73.4M | $121.8M | $159.0M |
| Stocks | 0 | $757000 | $7.1M | $11.5M | $13.0M | $16.2M | $26.8M | $34.0M | $45.0M | $52.0M |
| Actifs Courants | $498.1M | $244.5M | $522.4M | $851.0M | $1.30B | $856.6M | $883.9M | $732.2M | $817.1M | $951.0M |
| Immobilisations Corporelles | $17.1M | $21.8M | $20.0M | $74.7M | $114.0M | $176.2M | $259.7M | $290.6M | $265.9M | $267.0M |
| Goodwill | 0 | $44.4M | $44.4M | $44.4M | $44.4M | $44.4M | $44.4M | $44.4M | $44.4M | $44.0M |
| Actifs Incorporels | 0 | $141.5M | $129.2M | $129.0M | $131.1M | $130.8M | $160.1M | $166.3M | $178.3M | $176.0M |
| Actifs Totaux | $540.6M | $490.8M | $719.6M | $1.14B | $1.76B | $1.52B | $1.55B | $1.49B | $1.50B | $1.53B |
| Dettes Fournisseurs | $5.4M | $8.9M | $12.3M | $12.9M | $12.9M | $17.1M | $43.3M | $42.1M | $38.8M | $31.0M |
| Dette à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $81.0M |
| Passifs Courants | $60.3M | $71.0M | $74.7M | $103.3M | $189.6M | $181.4M | $261.2M | $280.4M | $344.2M | $384.0M |
| Dette à Long Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.17B |
| Passifs Totaux | $66.7M | $107.3M | $110.7M | $481.7M | $605.2M | $599.8M | $1.19B | $1.22B | $1.24B | $1.60B |
| Réserves | -$530.5M | -$832.7M | -$1.03B | -$1.43B | -$1.62B | -$2.07B | -$2.78B | -$3.39B | -$3.96B | -$4.53B |
| Capitaux Propres | $474.0M | $383.5M | $608.9M | $653.8M | $1.15B | $922.6M | $352.5M | $275.4M | $255.3M | -$80.0M |
| Dette Totale | 0 | 0 | 0 | $37.0M | $48.2M | $42.0M | $31.6M | $43.2M | $40.3M | $1.28B |
| Dette Nette | -$498.1M | -$244.5M | -$459.7M | -$718.2M | -$1.15B | -$698.2M | -$716.2M | -$534.0M | -$569.7M | $583.0M |
| Fonds de Roulement | $437.9M | $173.5M | $447.6M | $747.7M | $1.11B | $675.2M | $622.7M | $451.7M | $473.0M | $567.0M |
Santé financière
| Dette / Capitaux propres | -4.13 |
| Ratio de liquidité | 1.73 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -3.56 |
Rentabilité
| Rentabilité des capitaux propres | 392.35% |
| Rentabilité du capital investi | -53.48% |
| Rentabilité des actifs | -46.39% |
| Marge brute | 83.12% |
| Marge opérationnelle | -73.77% |
| Marge nette | -81.79% |
Entreprises liées: AAPG · APGE · CELC · CGON · CNTA · DYN · IDYA
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de RARE: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions